ClinicalTrials.gg
RecruitingNCT05559918DAPT-FOR-REALUpdated Apr 24, 2024

Dual-antiplatelet Therapy Strategies for Elective PCI in a Real-world Setting

An observational study in Coronary Artery Disease, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-24.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,462
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Coronary Artery Disease by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — 5 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Started
2022
with 2 others
Observational
7 of 11
4 open now
Registered
6th of 11
by date

Among the 11 studies in Coronary Artery Disease by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), this one is one of 3 that started in 2022, is one of 7 observational ones, and was the 6th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 11 studies in Coronary Artery Disease by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Coronary Artery Disease by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), or all of them as a file.
02

Study summary

To assess the safety and efficacy of in-laboratory clopidogrel loading dose administration before ad-hoc PCI versus clopidogrel preloading treatment in patients planned for diagnostic angiography with optional ad-hoc PCI.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Pretreatment
  • Diagnostic angiography
  • ad-hoc PCI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Consecutive patients aged 18 years and older who have been referred for diagnostic CAG due to symptoms suggestive of obstructive coronary artery disease with optional ad-hoc PCI.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult men and women aged at least 18 years
  • Scheduled for diagnostic CAG due to suspected obstructive coronary artery disease

Exclusion criteria

Exclusion Criteria:

  • Presence of for the use of clopidogrel ( or known allergy to clopidogrel, severe liver insufficiency, resent or active pathological bleeding, patients known to be poor CYP2C19 metabolizers, patients using pharmacological CYP2C19 inhibitors and inducers)
  • Patients using clopidogrel for other reasons than the scheduled diagnostic CAG (e.g. due to previous stroke)
  • Patients using P2Y12 inhibitors other than clopidogrel (e.g. prasugrel, ticagrelor, cangrelor)
  • Patients using VKA (e.g. acenocoumarol, fenprocoumon)
  • Patients using DOAC/NOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban)
  • Inability to give (e.g., language barrier)
  • Patients who have a documented mentioning of previous denial to any trial participation in the electronic patient dossier
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,462 participants (estimated)
Target follow-up
1 Month
Patient registry
Yes

Groups and cohorts

  • Preloading with clopidogrel
  • In-hospital loading with clopidogrel
06

What researchers measure

Primary outcomes

  1. Net adverse clinical events (NACE)

    The incidence rate of NACE (the composite of the clinical events all-cause death, myocardial infarction, definite/probable stent thrombosis, stroke and BARC type 2, -3 or -5 bleeding) wil be compared between groups at 30 days

    Time frame: 30 days

Secondary outcomes

  1. Bleeding (classified as BARC type 2, -3 and -5 bleeding)

    The incidence rate of bleeding (classified as BARC type 2, -3 and -5 bleeding) will be compared between groups

    Time frame: In-hospital, at 30 days

  2. Patient oriented clinical events (POCE)

    The incidence rate of POCE (the composite of clinical events all-cause death, stroke, myocardial infarction, and repeat revascularization) will be compared between groups

    Time frame: In-hospital, at 30 days

  3. All-cause mortality

    The incidence rate of all-cause mortality will be compared between groups

    Time frame: In-hospital, at 30 days

  4. Myocardial infarction

    The incidence rate of myocardial infarction will be compared between groups

    Time frame: In-hospital, at 30 days

  5. Stent thrombosis (definite/probable)

    The incidence rate of stent thrombosis (definite and probable) will be compared between groups

    Time frame: In-hospital, at 30 days

  6. Stroke

    The incidence rate of stroke will be compared between groups

    Time frame: In-hospital, at 30 days

  7. Repeat revascularisation

    The incidence rate of repeat revascularisation will be compared between groups

    Time frame: In-hospital, at 30 days

07

Study locations

2 of 2 sites recruiting
  • Amsterdam Universitair Medisch Centrum (AUMC) - Locatie AMC
    Amsterdam, Noord-Holland, Netherlands
    Recruiting
  • Amsterdam Universitair Medisch Centrum (AUMC) - Locatie VUMC
    Amsterdam, Noord-Holland, Netherlands
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Jul 2025, 33 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 33 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2022
First posted
Sep 29, 2022
StartActual
Oct 1, 2022
Primary completionEst.
Jul 30, 2025
CompletionEst.
Dec 31, 2025
Last update
Apr 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05559918
Responsible party
Ronak Delewi (Principal Investigator Dr. R Delewi, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Sep 29, 2022
Start date
Oct 1, 2022
Primary completion
Jul 30, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Apr 24, 2024

Study contacts

Ronak Delewi, MD, PhD
Contact
r.delewi@amsterdamumc.nl
+31(0)20 566 9111
Ronak Delewi, MD, PhD
principal investigator · Amsterdam University Medical Center, location AMC

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion